Cellular signalling as a target in cancer chemotherapy. Phospholipid analogues as inhibitors of mitogenic signal transduction
- 31 December 1996
- journal article
- Published by Elsevier in Advances in Enzyme Regulation
- Vol. 36, 385-407
- https://doi.org/10.1016/0065-2571(95)00015-1
Abstract
No abstract availableKeywords
This publication has 55 references indexed in Scilit:
- Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic MutationsScience, 1994
- Phospholipase D activation in fibroblast membranes by the α and β isoforms of protein kinase CFEBS Letters, 1994
- Phosphatidylcholine breakdown and signal transductionBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1994
- Suramin, an Active Drug for Prostate Cancer: Interim Observations in a Phase I TrialJNCI Journal of the National Cancer Institute, 1993
- Mediation of growth factor induced DNA synthesis and calcium mobilization by Gq and Gi2.The Journal of cell biology, 1993
- Point mutation of an FGF receptor abolishes phosphatidylinositol turnover and Ca2+ flux but not mitogenesisNature, 1992
- The phospholipid analogue, hexadecylphosphocholine, inhibits protein kinase C in vitro and antagonises phorbol ester-stimulated cell proliferationEuropean Journal of Cancer and Clinical Oncology, 1991
- Phospholipase C-mediated hydrolysis of phosphatidlycholine is an important step in PDGF-stimulated DNA synthesisCell, 1990
- Suramin: A new therapeutic conceptEuropean Journal of Cancer and Clinical Oncology, 1990
- THE PROTEIN KINASE C FAMILY: HETEROGENEITY AND ITS IMPLICATIONSAnnual Review of Biochemistry, 1989